False positives in the early stages of drug discovery

Current Medicinal Chemistry

Volumn 17, Issue 34, 2010, Pages 4231-4255

  Sink R ^a   Gobec, S ^a   Pecar S ^a   Zega, A ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Aggregate based promiscuous inhibitors; Drug discovery; Mechanism of false positive inhibition; Methods for detecting false positives; Reactive compounds

Indexed keywords

ADRENALIN; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BAICALEIN; BENZYL BENZOATE; CARBIDOPA; CEFACLOR; CLIOQUINOL; CLOTRIMAZOLE; DELAVIRDINE; DISULFIRAM; DITHIOTHREITOL; DNA; ECONAZOLE; ETACRYNIC ACID; FLUCONAZOLE; FUNCTIONAL GROUP; GLIBENCLAMIDE; GLUTATHIONE; LIDOCAINE; MEFENAMIC ACID; MICONAZOLE; NICARDIPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; OXAPROZIN; PHOSPHOTRANSFERASE INHIBITOR; SULCONAZOLE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALYTICAL ERROR; ARTICLE; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG DNA BINDING; DRUG EFFECT; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DYNAMIC LIGHT SCATTERING; ELECTRON MICROSCOPY; ENZYME INHIBITION; FLUORESCENCE SPECTROSCOPY; HIGH THROUGHPUT SCREENING; INHIBITION KINETICS; LIGHT SCATTERING; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRION DISEASE; SENSITIVITY ANALYSIS; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

BIOLOGICAL ASSAY; COMPUTER SIMULATION; DRUG DISCOVERY; FALSE POSITIVE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; STATISTICS AS TOPIC;

EID: 78650674952     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793348545     Document Type: Article

References (88)

1. Pereira, D. A.; Williams, J. A. Origin and evolution of high throughput screening. Br. J. Pharmacol., 2007, 152(1), 53-61.
2. Diller, D. J.; Hobbs, D. W. Deriving knowledge through data mining high-throughput screening data. J. Med. Chem., 2004, 47(25), 6373-6383.
3. Lane, S. J.; Eggleston, D. S.; Brinded, K. A.; Hollerton, J. C.; Taylor, N. L.; Readshaw, S. A. Defining and maintaining a high quality screening collection: the GSK experience. Drug Discov. Today, 2006, 11 (5-6), 267-272.
4. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J. Chem. Inf. Comput. Sci., 2004, 44(2), 643-651.
5. Sirois, S.; Hatzakis, G.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Assessment of chemical libraries for their druggability. Comput. Biol. Chem., 2005, 29(1), 55-67.
6. Verheij, H. J., Leadlikeness and structural diversity of synthetic screening libraries. Mol. Divers., 2006, 10(3), 377-388.
7. Chuprina, A.; Lukin, O.; Demoiseaux, R.; Buzko, A.; Shivanyuk, A. Drug-and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers. J. Chem. Inf. Model., 2010, 50(4), 470-479.
8. Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem., 2010, 53(7), 2719-2740.
9. Lajiness, M. S.; Maggiora, G. M.; Shanmugasundaram, V. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. J. Med. Chem., 2004, 47(20), 4891-4896.
10. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today, 2003, 8(2), 86-96.
11. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem., 2002, 45(8), 1712-1722.
12. Babaoglu, K.; Simeonov, A.; Lrwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi, M. P.; Maltby, D. A.; Jadhav, A.; Inglese, J.; Austin, C. P.; Shoichet, B. K. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem., 2008, 51(8), 2502-2511.
13. Shapiro, A. B.; Walkup, G. K.; Keating, T. A. Correction for interference by test samples in high-throughput assays. J. Biomol. Screen., 2009, 14(8), 1008-1016.
14. Pearce, B. C.; Sofia, M. J.; Good, A. C.; Drexler, D. M.; Stock, D. A. An empirical process for the design of high-throughput screening deck filters. J. Chem. Inf. Model., 2006, 46(3), 1060-1068.
15. Rishton, G. M. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. Curr. Opin. Chem. Biol., 2008, 12(3), 340-351.
16. Simeonov, A.; Jadhav, A.; Thomas, C. J.; Wang, Y. H.; Huang, R. L.; Southall, N. T.; Shinn, P.; Smith, J.; Austin, C. P.; Auld, D. S.; Inglese, J. Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem., 2008, 51(8), 2363-2371.
17. Auld, D. S.; Southall, N. T.; Jadhav, A.; Johnson, R. L.; Diller, D. J.; Simeonov, A.; Austin, C. P.; Inglese, J. Characterization of chemical libraries for luciferase inhibitory activity. J. Med. Chem., 2008, 51(8), 2372-2386.
18. Bakhtiarova, A.; Taslimi, P.; Elliman, S. J.; Kosinski, P. A.; Hubbard, B.; Kavana, M.; Kemp, D. M. Resveratrol inhibits firefly luciferase. Biochem. Bioph. Res. Comun., 2006, 351(2), 481-484.
19. Di, L.; Kerns, E. H. Biological assay challenges from compound solubility: strategies for bioassay optimization. Drug Discov. Today 2006, 11 (9-10), 446-451.
20. Smith, G. K.; Barrett, D. G.; Blackburn, K.; Cory, M.; Dallas, W. S.; Davis, R.; Hassler, D.; McConnell, R.; Moyer, M.; Weaver, K. Expression, preparation, and high-throughput screening of caspase-8: Discovery of redox-based and steroid diacid inhibition. Arch. Biochem. Biophys., 2002, 399(2), 195-205.
21. Bova, M. P.; Mattson, M. N.; Vasile, S.; Tam, D.; Holsinger, L.; Bremer, M.; Hui, T.; McMahon, G.; Rice, A.; Fukuto, J. M. The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide. Arch. Biochem. Biophys., 2004, 429(1), 30-41.
22. Brisson, M.; Nguyen, T.; Wipf, P.; Joo, B.; Day, B. W.; Skoko, J. S.; Schreiber, E. M.; Foster, C.; Bansal, P.; Lazo, J. S. Redox regulation of Cdc25B by cell-active quinolinediones. Mol. Pharmacol., 2005, 68(6), 1810-1820.
23. Percival, M. D.; Ouellet, M.; Campagnolo, C.; Claveau, D.; Li, C. Inhibition of cathepsin K by nitric oxide donors: Evidence for the formation of mixed disulfides and a sulfenic acid. Biochemistry, 1999, 38(41), 13574-13583.
24. Potashman, M. H.; Duggan, M. E. Covalent Modifiers: An Orthogonal Approach to Drug Design. J. Med. Chem., 2009, 52(5), 1231-1246.
25. Rishton, G. M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today 1997, 2(9), 382-384.
26. Mahajan, M. K.; Evans, C. A. Dual negative precursor ion scan approach for rapid detection of glutathione conjugates using liquid chromatography/tandem mass spectrometry. Rapid. Commun. Mass. Spectrom., 2008, 22(7), 1032-1040.
27. Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. H.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E. V.; DeLisle, D. M.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem., 1998, 41(15), 2806-2818.
28. Matthews, D. A.; Dragovich, P. S.; Webber, S. E.; Fuhrman, S. A.; Patick, A. K.; Zalman, L. S.; Hendrickson, T. F.; Love, R. A.; Prins, T. J.; Marakovits, J. T.; Zhou, R.; Tikhe, J.; Ford, C. E.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Brothers, M. A.; DeLisle, D. M.; Worland, S. T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(20), 11000-7.
29. Blanchard, J. E.; Elowe, N. H.; Huitema, C.; Fortin, P. D.; Cechetto, J. D.; Eltis, L. D.; Brown, E. D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol., 2004, 11(10), 1445-53.
30. Epps, D. E.; Taylor, B. M. A competitive fluorescence assay to measure the reactivity of compounds. Anal. Biochem., 2001, 295(1), 101-6.
31. Rastelli, G.; Costantino, L.; Albasini, A. A model of the interaction of substrates and inhibitors with xanthine oxidase. J. Am. Chem. Soc., 1997, 119(13), 3007-3016.
32. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem., 2003, 46(20), 4265-4272.
33. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem., 2003, 46(8), 1478-1483.
34. Malvezzi, A.; de Rezende, L.; Izidoro, M. A.; Cezari, M. H. S.; Juliano, L.; Amaral, A. T. D. Uncovering false positives on a virtual screening search for cruzain inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 350-354.
35. Reddie, K. G.; Roberts, D. R.; Dore, T. M. Inhibition of kinesin motor proteins by adociasulfate-2. J. Med. Chem., 2006, 49(16), 4857-4860.
36. Liu, H. Y.; Wang, Z. H.; Regni, C.; Zou, X. Q.; Tipton, P. A. Detailed kinetic studies of an aggregating inhibitor; Inhibition of phosphomannomutase/ phosphoglucomutase by Disperse Blue 56. Biochemistry, 2004, 43(27), 8662-8669.
37. Feng, B. Y.; Toyama, B. H.; Wille, H.; Colby, D. W.; Collins, S. R.; May, B. C. H.; Prusiner, S. B.; Weissman, J.; Shoichet, B. K. Small-molecule aggregates inhibit amyloid polymerization. Nat. Chem. Biol., 2008, 4(3), 197-199.
38. Frenkel, Y. V.; Clark, A. D.; Das, K.; Wang, Y. H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem., 2005, 48(6), 1974-1983.
39. Coan, K. E. D.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J. Am. Chem. Soc., 2008, 130(29), 9606-9612.
40. Coan, K. E. D.; Maltby, D. A.; Burlingame, A. L.; Shoichet, B. K. Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding. J. Med. Chem., 2009, 52(7), 2067-2075.
41. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem., 2003, 46(21), 4477-4486.
42. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J. Med. Chem., 2002, 45(1), 137-142.
43. Jenkins, J. L.; Kao, R. Y. T.; Shapiro, R. Virtual screening to enrich hit lists from high-throughput screening: A case study on small-molecule inhibitors of angiogenin. Proteins, 2003, 50(1), 81-93.
44. Carlson, E. E.; May, J. F.; Kiessling, L. L. Chemical probes of UDP-galactopyranose mutase. Chem. Biol., 2006, 13(8), 825-837.
45. Powers, J. P.; Piper, D. E.; Li, Y.; Mayorga, V.; Anzola, J.; Chen, J. M.; Jaen, J. C.; Lee, G.; Liu, J.; Peterson, M. G.; Tonn, G. R.; Ye, Q.; Walker, N. P.; Wang, Z. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem., 2006, 49(3), 1034-46.
46. Lee, G.; Piper, D. E.; Wang, Z. L.; Anzola, J.; Powers, J.; Walker, N.; Li, Y. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J. Mol. Biol., 2006, 357(4), 1051-1057.
47. Carter, P. H.; Scherle, P. A.; Muckelbauer, J. K.; Voss, M. E.; Liu, R. Q.; Thompson, L. A.; Tebben, A. J.; Solomon, K. A.; Lo, Y. C.; Li, Z.; Strzemienski, P.; Yang, G.; Falahatpisheh, N.; Xu, M.; Wu, Z.; Farrow, N. A.; Ramnarayan, K.; Wang, J.; Rideout, D.; Yalamoori, V.; Domaille, P.; Underwood, D. J.; Trzaskos, J. M.; Friedman, S. M.; Newton, R. C.; Decicco, C. P. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(21), 11879-84.
48. Voss, M. E.; Carter, P. H.; Tebben, A. J.; Scherle, P. A.; Brown, G. D.; Thompson, L. A.; Xu, M. Z.; Lo, Y. C.; Yang, G. J.; Liu, R. Q.; Strzemienski, P.; Everlof, J. G.; Trzaskos, J. M.; Decicco, C. P. Both 5-Arylidene-2- thioxodihydropyrimidine-4, 6 (1H, 5H)-diones and 3-Thioxo-2, 3-dihydro-1H-imidazo[1, 5-a]indol-1-ones are light-dependent tumor necrosis Factor-alpha antagonists. Bioorg. Med. Chem. Lett., 2003, 13(3), 533-538.
49. Forino, M.; Johnson, S.; Wong, T. Y.; Rozanov, D. V.; Savinov, A. Y.; Li, W.; Fattorusso, R.; Becattini, B.; Orry, A. J.; Jung, D. W.; Abagyan, R. A.; Smith, J. W.; Alibek, K.; Liddington, R. C.; Strongin, A. Y.; Pellecchia, M. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(27), 9499-9504.
50. Caulfield, M. J.; McAllister, D. J.; Russo, T.; Solomon, D. H. Complexes of benzene-1, 2-diol Mannich bases. II - Novel aluminium (III) complexes. Aust. J. Chem., 2001, 54(6), 383-389.
51. Occhipinti, G.; Bjorsvik, H. R.; Tornroos, K. W.; Jensen, V. R. Ruthenium alkylidene complexes of chelating amine Ligands.organometallics, 2007, 26(24), 5803-5814.
52. Xie, Y. S.; Liu, Q. L.; Jiang, H.; Ni, J. Novel complexes of ligands containing phenol and alcohol groups: From polynuclear cluster, 1D coordination polymer to 2D supramolecular assemblies. Eur. J. Inorg. Chem., 2003, (22), 4010-4016.
53. Ghailane, R.; Marakchi, K.; Komiha, N.; Kabbaj, O. K.; Chraibi, M.; Habbadi, N.; Dartiguenave, M. A theoretical investigation of the conformational aspects of aminophenols and of their complexation with BF2+ and ZnCl2. J. Mol. Struc., 2000, 531, 223-239.
54. Koh, L. L.; Ranford, J. O.; Robinson, W. T.; Svensson, J. O.; Tan, A. L. C.; Wu, D. Q. Model for the reduced Schiff base intermediate between amino acids and pyridoxal: Copper (II) complexes of N-(2-hydroxbenzyl) amino acids with nonpolar side chains and the crystal structures of [Cu (N-(2-hydroxbenzyl)-D, L-alanine) (phen)]center dot H2O and [Cu (N-(2-hydroxybenzyl)-D, L-alanine) (imidazole)]. Inorg. Chem., 1996, 35(22), 6466-6472.
55. Herzig, Y.; Lerman, L.; Goldenberg, W.; Lerner, D.; Gottlieb, H. E.; Nudelman, A. Hydroxy-1-aminoindans and derivatives: Preparation, stability, and reactivity. J. Org. Chem., 2006, 71(11), 4130-4140.
56. Weinert, E. E.; Dondi, R.; Colloredo-Melz, S.; Frankenfield, K. N.; Mitchell, C. H.; Freccero, M.; Rokita, S. E. Substituents on quinone methides strongly modulate formation and stability of their nucleophilic adducts. J. Am. Chem. Soc., 2006, 128(36), 11940-11947.
57. McLean, L. R.; Zhang, Y.; Li, H.; Li, Z. Y.; Lukasczyk, U.; Choi, Y. M.; Han, Z. N.; Prisco, J.; Fordham, J.; Tsay, J. T.; Reiling, S.; Vaz, R. J.; Li, Y. Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening. Bioorg. Med. Chem. Lett., 2009, 19(23), 6717-6720.
58. Ledesma, G. N.; Sierra, M. G.; Escandar, G. M. Spectroscopic and theoretical study of aromatic alpha-hydroxy hydrazones and their copper (II) complexes in dioxane-water mixtures. Polyhedron, 1998, 17(9), 1517-1523.
59. Ainscough, E. W.; Brodie, A. M.; Denny, W. A.; Finlay, G. J.; Gothe, S. A.; Ranford, J. D. Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. J. Inorg. Biochem., 1999, 77 (3-4), 125-133.
60. Dilovic, I.; Rubcic, M.; Vrdoljak, V.; Pavelic, S. K.; Kralj, M.; Piantanida, I.; Cindric, M. Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity. Bioorg. Med. Chem., 2008, 16(9), 5189-5198.
61. Ifa, D. R.; Rodrigues, C. R.; de Alencastro, R. B.; Fraga, C. A. M.; Barreiro, E. J. A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. J. Mol. Struc., 2000, 505, 11-17.
62. Meissner, J. W. G.; Vanderlaan, A. C.; Pandit, U. K. Reduction of 5-Arylidenebarbiturate Derivatives by Thiols. Tetrahedron Lett., 1994, 35(17), 2757-2760.
63. Tanaka, K.; Chen, X.; Yoneda, F. Oxidation of Thiol with 5-Arylidene-1, 3-Dimethylbarbituric Acid - Application to Synthesis of Unsymmetrical Disulfide. Tetrahedron, 1988, 44(11), 3241-3249.
64. Tanaka, K.; Chen, X.; Kimura, T.; Yoneda, F. 5-Arylidene 1, 3-Dimethylbarbituric Acid-Derivatives, Mild Organic Oxidants for Allylic and Benzylic Alcohols. Chem. Pharm. Bull,. 1988, 36(1), 60-69.
65. Pervaiz, S.; Harriman, A.; Gulliya, K. S. Protein damage by photoproducts of merocyanine-540. Free Radic. Biol. Med., 1992, 12(5), 389-396.
66. Sleno, L.; Staack, R. F.; Varesio, E.; Hopfgartner, G. Investigating the in vitro metabolism of fipexide: characterization of reactive metabolites using liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21(14), 2301-2311.
67. Li, W. W.; Heinze, J.; Haehnel, W. Site-specific binding of quinones to proteins through thiol addition and additionelimination reactions. J. Am. Chem. Soc., 2005, 127(17), 6140-6141.
68. Liu, X. W.; Sok, D. E. Identification of alkylation-sensitive target chaperone proteins and their reactivity with natural products containing Michael acceptor. Arch. Pharm. Res., 2003, 26(12), 1047-1054.
69. Huth, J. R.; Mendoza, R.; Olejniczak, E. T.; Johnson, R. W.; Cothron, D. A.; Liu, Y. Y.; Lerner, C. G. Chen, J.; Hajduk, P. J., ALARM NMR: A rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc., 2005, 127(1), 217-224.
70. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. W. Effect of detergent on "promiscuous" inhibitors. J. Med. Chem., 2003, 46(16), 3448-3451.
71. Feng, B. Y.; Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc., 2006, 1(2), 550-553.
72. Coan, K. E. D.; Shoichet, B. K. Stability and equilibria of promiscuous aggregates in high protein milieus. Mol. Biosyst., 2007, 3(3), 208-213.
73. Coval, M. L., Analysis of Hill Interaction Coefficients and Invalidity of Kwon and Brown Equation. J. Biol. Chem., 1970, 245(23), 6335-6.
74. Walters, W. P.; Namchuk, M. Designing screens: How to make your hits a hit. Nat. Rev. Drug Discov., 2003, 2(4), 259-266.
75. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem., 2006, 49(25), 7274-7277.
76. Ellman, G. L. Tissue sulfhydryl groups. Arch. Biochem. Biophys., 1959, 82(1), 70-7.
77. Johnston, P. A.; Soares, K. M.; Shinde, S. N.; Foster, C. A.; Shun, T. Y.; Takyi, H. K.; Wipf, P.; Lazo, J. S. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug. Dev. Technol., 2008, 6(4), 505-18.
78. Lor, L. A.; Schneck, J.; McNulty, D. E.; Diaz, E.; Brandt, M.; Thrall, S. H.; Schwartz, B. A simple assay for detection of smallmolecule redox activity. J. Biomol. Screen., 2007, 12(6), 881-90.
79. Walters, W. P.; Murcko, M. A. Prediction of 'drug-likeness'. Adv. Drug Deliv. Rev., 2002, 54(3), 255-271.
80. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L.; Ramsden, N. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci., 1999, 39(5), 897-902.
81. Wyatt, P. J. Light-scattering and the absolute characterization of macromolecules. Anal. Chim. Acta., 1993, 272(1), 1-40.
82. Santos, N. C.; Castanho, M. A. R. B. Teaching light scattering spectroscopy: The dimension and shape of tobacco mosaic virus. Biophys. J., 1996, 71(3), 1641-1650.
83. Brenk, R.; Meyer, E. A.; Reuter, K.; Stubbs, M. T.; Garcia, G. A.; Diederich, F.; Klebe, G. Crystallographic study of inhibitors of tRNA-guanine transglycosylase suggests a new structure-based pharmacophore for virtual screening. J. Mol. Biol., 2004, 338(1), 55-75.
84. Wang, L. Z.; Kenyon, G. L.; Johnson, K. A. Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. J. Biol. Chem., 2004, 279(37), 38424-32.
85. Soelaiman, S.; Wei, B. Q. Q.; Bergson, P.; Lee, Y. S.; Shen, Y. Q.; Mrksich, M.; Shoichet, B. K.; Tang, W. J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem., 2003, 278(28), 25990-25997.
86. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem., 2008, 51(3), 574-580.
87. Cai, L. F.; Gochin, M. Colloidal aggregate detection by rapid fluorescence measurement of liquid surface curvature changes in multiwell plates. J. Biomol. Screen., 2007, 12(7), 966-971.
88. Dalvit, C.; Caronni, D.; Mongelli, N.; Veronesi, M.; Vulpetti, A. NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr. Drug. Discov. Technol., 2006, 3(2), 115-24.